Aptalis Holdings, the pharmaceutical company focused on gastrointestinal diseases and cystic fibrosis, filed to raise $500 million in an initial public offering in the U.S. The figure is a placeholder used to calculate fees and may change. Aptalis plans to use the proceeds to repay debt, and some of the company’s existing stockholders also plan to sell shares, according to today’s filing.
Help employers find you! Check out all the jobs and post your resume.
